| Site | Number of cases* | Number of cases with organism specified† | Group A Streptococci† | Streptococci(not otherwise classified)† | Staphylococcusaureus† | Staphylococcusepidermidis† | Staphylococcus(not otherwise classified)† | Meningococcal serogroup B† | Mycoplasma† |
| Blood | 23 (21%) | 16 (70%) | 11 (69%) | 1 (6%) | 2 (12%) | 1 (6%) | 0 | 1 (6%) | 0 |
| Skin | 16 (14%) | 14 (88%) | 5‡ (36%) | 0 | 9‡ (64%) | 0 | 2 (14%) | 0 | 0 |
| Chest/lung | 10 (9%) | 4 (40%) | 0 | 0 | 2 (50%) | 0 | 1 (25%) | 0 | 1 (25%) |
| Soft tissue | 12 (11%) | 6 (50%) | 4 (67%) | 0 | 1 (17%) | 0 | 1 (17%) | 0 | 0 |
| Bone/joint | 3 (3%) | 3 (100%) | 0 | 0 | 3 (100%) | 0 | 0 | 0 | 0 |
| Airway | 3 (3%) | 3 (100%) | 3 (100%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Nasal | 2 (2%) | 2 (100%) | 2‡ (100%) | 0 | 1‡(50%) | 0 | 0 | 0 | 0 |
| Middle ear | 1 (1%) | 1 (100%) | 1 (100%) | 0 | 0 | 0 | 0 | 0 | 0 |
*Percentages are of total cases (n = 112); †percentages are of total infections at this site; ‡two of the skin site cases and one of the nasal site cases had mixed Group A Streptococcus/S aureus infection.